New England Journal of Medicine· 2018Q1

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam, Edmund K. Waller et al.

4,070citations
Q1SCImago
2018year

Short summary

Tisagenlecleucel, a CAR T-cell therapy, achieved a 52% overall response rate (40% complete response) in adults with relapsed/refractory diffuse large B-cell lymphoma ineligible for stem-cell transplant.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Oncology

OncologyMedicine